spacer
home > ebr > autumn 2007 > thinking outside the box
PUBLICATIONS
European Biopharmaceutical Review

Thinking Outside the Box

Richard Barratt and Natalie Kingston at Morgan Lewis examine the use of outsourcing in the life sciences industry

The life science industry is in a state of constant flux – largely as a result of an unrelenting need for innovation and the threat of competition, both of which can have a dramatic impact on a life science company’s profits and future. History has shown that companies, whether pharmaceutical, biotechnology or device focused, must find ways to adapt and be flexible in this challenging environment in order to truly prosper.

THE IMPORTANCE OF OUTSOURCING TO THE INDUSTRY

In the last decade there have been two important developments in practices in the life science sector. The first of these has been a shift in focus away from pure innovation in favour of strategic partnerships and acquisitions as a means of growing product portfolios and increasing market presence. The second has been a move to drive down costs by outsourcing internal processes and procedures, thereby freeing up funds for selective R&D projects and to fund strategic partnerships and acquisitions. As a result, outsourcing of critical functions is now a key strategy for most life science companies.

The types of operations which life science companies can outsource are many and varied. Numerous functions have long been outsourced to contract research or similar organisations – clinical trial and data management, pharmacovigilance and quality assurance processes are a few examples. However, the more recent advent of offshore outsourcing to countries such as India and South America, and the focus on larger outsourcing arrangements of mainstream finance and accounting, human resources, information technology and other business processes, has led life science companies to realise the benefits of outsourcing these types of functions as well.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Barratt is a Partner in the Business and Finance Practice in London. He joined Morgan Lewis in 2004 and is head of the UK outsourcing practice. Over the last 20 years Richard has developed a substantial commercial intellectual property and technology practice. A large part of his work involves international joint and cooperative ventures for the development and exploitation of products and technology. He has advised corporations, government authorities and financial institutions on the procurement of IT systems and services, as well as distribution and supply arrangements in a variety of commercial and industrial sectors.

Natalie Kingston is an Associate in Morgan Lewis’s Business and Finance Practice and is a member of the Global Outsourcing Group. She handles a wide range of regulatory matters, commercial agreements and transactions for clients in the life sciences sector. In addition to acting for pharmaceutical and medical device companies, she also has particular experience advising in relation to foods and cosmetics. Natalie is involved with outsourcing and general commercial and corporate issues including joint ventures, intellectual property and technology agreements.

spacer
Richard Barratt
spacer
spacer
spacer
Natalie Kingston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Data custodianship of connected devices, environmental impact and adherence technologies highlighted at Pharmapack Europe 2020

Paris, 19th February 2020: Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at the recent Pharmapack Europe (#pharmapackeu). The event is widely seen as an excellent yardstick of the industry’s prospects for the year ahead. Encouragingly, the event played host a record 411 exhibiting companies, 5366 attendees and 325 delegates.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement